



Respiratory Viruses and Antiviral Immunity

Guest Editors:

Dr. Andreu Comas-Garcia

Department of Microbiology,
School of Medicine, Universidad
Autónoma San Luis Potosí, Av.
Venustiano Carranza 2405,
Lomas Los Filtros, San Luis
Potosí 78210, Mexico

Dr. Sofia Bernal-Silva

School of Medicine, Department
of Microbiology, Universidad
Autónoma de San Luis Potosí,
San Luis Potosí, México

Prof. Dr. Maria Grazia Cusi

Department of Biotechnology,
Microbiology Section, University
of Siena, Siena, Italy

Deadline for manuscript
submissions:

closed (31 January 2026)

Message from the Guest Editors

Dear Colleagues,

The respiratory tract is a major portal of entry for viruses into the body. Various strategies exist to control respiratory virus replication and to limit immune-mediated inflammation and tissue injury. This Special Issue is interested in the contributions of physical and chemical barriers to infection and the various innate immune mechanisms and cell types mediating host responses to virus infections—both innate and adaptive immune responses. Particularly, the features of interest include the protective mechanisms and their pathophysiological implications in viral respiratory infections. We are pleased to invite you to contribute to this Special Issue, which aims to describe, interpret, and analyze the role of the antiviral response in various aspects: as a protective barrier, a mechanism of containment or elimination, and as a basis for the pathophysiology of viral respiratory infections. Within this framework, particular interest is given to questions such as what contributes to viral reinfections and the antiviral response leading to disease and damage and how this understanding can be used to develop therapeutic strategies that include vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)